1. MAPK/ERK Pathway
    Stem Cell/Wnt
  2. ERK

ERK

ERKs (Extracellular-signal-regulated kinases) are widely expressed protein kinase intracellular signalling molecules that are involved in functions including the regulation of meiosis, mitosis, and postmitotic functions in differentiated cells. Many different stimuli, including growth factors, cytokines, virus infection, ligands for heterotrimeric G protein-coupled receptors, transforming agents, and carcinogens, activate the ERK pathway. In the MAPK/ERK pathway, Ras activates c-Raf, followed by mitogen-activated protein kinase kinase (abbreviated as MKK, MEK, or MAP2K) and then MAPK1/2 (below). Ras is typically activated by growth hormones through receptor tyrosine kinases and GRB2/SOS, but may also receive other signals. ERKs are known to activate many transcription factors, such as ELK1, and some downstream protein kinases. Disruption of the ERK pathway is common in cancers, especially Ras, c-Raf and receptors such as HER2.

ERK Related Products (28):

Cat. No. Product Name Effect Purity
  • HY-50846
    SCH772984 Inhibitor 98.06%
    SCH772984 potently inhibits ERK1 and ERK2 activity with IC50 values of 4 and 1 nM, respectively.
  • HY-15947
    GDC-0994 Inhibitor 99.57%
    GDC-0994 is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
  • HY-N0003
    Honokiol Activator 99.90%
    Honokiol is a hydroxylated biphenyl compound, which inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2.
  • HY-19696A
    Tauroursodeoxycholate Sodium Inhibitor 98.02%
    Tauroursodeoxycholate Sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
  • HY-15615A
    TIC10 Inhibitor 99.68%
    TIC10 is a potent, orally active, and stable TRAIL inducer, also inhibits Akt and ERK activity.
  • HY-111483
    AZD-0364 Inhibitor
    AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM.
  • HY-112082
    BAY885 Inhibitor
    BAY885 is a novel ERK5 inhibitor.
  • HY-19700
    trans-Zeatin Inhibitor 99.28%
    trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; also inhibits UV-induced MEK/ERK activation.
  • HY-14443
    XMD8-92 Inhibitor 99.72%
    XMD8-92 is a highly selective ERK5/BMK1 inhibitor with dissociation constant (Kd) value of 80 nM.
  • HY-N0431
    Astragaloside IV Inhibitor 99.15%
    Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.
  • HY-14178
    VX-11e Inhibitor 98.68%
    VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with Ki < 2 nM.
  • HY-12275
    FR 180204 Inhibitor 99.60%
    FR 180204 is an ATP-competitive, selective ERK inhibitor with Ki of 0.31 μM and 0.14 μM for ERK1 and ERK2, respectively.
  • HY-15816
    VRT752271 Inhibitor 99.87%
    VRT752271 is a reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with Km of <0.3 nM against ERK2.
  • HY-N2312
    Mogrol Inhibitor 98.06%
    Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.
  • HY-N0590
    Corynoxeine Inhibitor 99.91%
    Corynoxeine, isolated from the hook of Uncaria rhynchophylla, is a potent ERK1/ERK2 inhibitor of key PDGF-BB-induced vascular smooth muscle cells (VSMCs) proliferation.
  • HY-101494
    LY3214996 Inhibitor 99.87%
    LY3214996 is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays.
  • HY-18932
    DEL-22379 Inhibitor 99.84%
    DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a Kd estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC50 of ~0.5 μM.
  • HY-14403
    ERK5-IN-1 Inhibitor 98.62%
    ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM.
  • HY-104047
    LM22B-10 Activator 98.81%
    LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.
  • HY-15665
    XMD17-109 Inhibitor 99.44%
    XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC50 of 162 nM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.